Unlabelled: Implementation of ultrasonography (USG), computed tomography (CT) and magnetic resonance imaging (MRI) into abdominal cavity diagnostics enabled early detection of cT1 graded renal cancers. According to European Association of Urology (EAU) and Polish urological Association (PUA) recommended method of treatment is sparing resection of renal parenchyma with tumour-nephron-sparing surgery (NSS). In selected cases other methods such as thermal ablation (TA) or cryoablation can be introduced /1/.

Objectives: To evaluate the results of treatment of cT1 renal tumours with the use of NSS and TA methods.

Material And Methods: 140 patients with cT1 renal carcinoma were treated in 2nd Department of Urology of Medical University of Lodz between 2014 and 2017. Neuron-sparing surgery was performed in 56 cases (40%), while percutane-ous thermal ablation (TA) in 84 cases (60%). Demographic data, clinical data (lab results, Charlson index), nephrometry data (tumour size, location, R.E.N.A.L. score) post-operative data (Clavien-Dindo classifica-tion) were investigated. Histopathology results, Fuhrman malignancy grading, as total three-year survival of patients were evaluated. The following methods were used for statistical evaluation: Chi2, Fisher, W Shapiro-Wilk, U Mann-Whitney tests, Kaplan-Meier's curve and Cox model. The results were displayed in a form of median and upper and lower quartile values (25-75%).

Results: No statistical differences in gender nor left/right kidney location were observed. Patients, who underwent TA were at average 10 years older and had multiple comorbidities (median age for TA was 79, for NSS 68; median Charlson index for TA was 5 and for NSS was 3). TA patients had lesser haematological values (Hb, Ht). R.E.N.A.L. scoring demonstrated comparable nephrometry in both groups. NSS procedure was open laparotomy without temporary clamping of renal vessels. Surgical margins of resected tumours were negative. TA was performed with Cool-Tip Covidienequipment with the use of Cluster electrode and was ultraso-nography-guided. Post-treatment complications evaluated with the use of Clavien-Dindo classification were slightly more frequent for NSS method. Patients after NSS were discharged at average after 8.5 days and after TA after 3 days. Histopathological type and Fuhrman malignancy grading were comparable in both groups. TA treated patients' death risk was 9-fold of that observed in NSS treated patients. There was 1 death for each group in perioperative period.

Conclusion: 1. NSS was associated with slightly higher side effect rate but resulted in prolonged survival. 2. TA was applied to elderly patients with comorbidities. Despite less invasive treatment this group had poorer/reduced survival. 3. Charlson Comorbidity Index (CCI) and the treatment method were relevant survival factors in patients treated due to cT1 renal cancer tumours.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956074PMC
http://dx.doi.org/10.3390/jpm12030495DOI Listing

Publication Analysis

Top Keywords

ct1 renal
16
thermal ablation
12
nss
10
renal
9
renal carcinoma
8
surgery nss
8
patients
8
fuhrman malignancy
8
malignancy grading
8
ct1
5

Similar Publications

Although partial nephrectomy (PN) is preferred over radical nephrectomy (RN) for preserving renal function in patients with cT1 renal cancer, its impact on cardiovascular events (CVe) remains controversial. This study aimed to compare PN and RN in regard to the occurrence of CVe, including cerebrovascular events and exacerbation of hypertension (HT). We retrospectively analyzed 418 consecutive patients who underwent PN or RN for cT1 renal cancer.

View Article and Find Full Text PDF
Article Synopsis
  • Upstaging to pT3a after partial nephrectomy for cT1 renal cell carcinoma (RCC) is uncommon, occurring in 3.6% of cT1a and 19% of cT1b patients within a study of 389 cases from 2011-2022.
  • The median tumor size for upstaged cases was 43 mm, and during a 59-month follow-up, there were six recurrence events, highlighting a significant risk for those with Fuhrman grade ≥3.
  • Five-year survival rates were reported as 75.7% for metastasis-free survival, 96.2% for cancer-specific survival, and 88.1% overall, indicating
View Article and Find Full Text PDF

Purpose: To assess active surveillance (AS) adherence for prostate cancer (PCa) in a "real-world" clinical practice.

Materials And Methods: We utilized our institutional database which was built by interrogating electronic medical records for all men who got diagnosed with PCa from 1995 to 2022. Our cohort included all patients aged < 76 years, with PCa Gleason Grade (GG) 1 or 2, ≤ cT2c, PSA ≤ 20 ng/ml at diagnosis, enrolled on AS, and with at least one biopsy after diagnosis.

View Article and Find Full Text PDF

Introduction And Objective: It remains unknown whether the use of nephron sparing intervention (NSI) is impacted with delayed intervention after a period of active surveillance (AS) compared with immediate intervention for patients with clinically localized renal masses ≤7cm (cT1RMs). We hypothesized that the proportion of patients undergoing NSI is similar among patients undergoing immediate and delayed intervention for cT1RMs.

Methods: We retrospective reviewed the prospectively maintained Michigan Urological Surgery Improvement Collaborative (MUSIC) registry for patients undergoing intervention for cT1RMs from 05/2017 to 09/2023.

View Article and Find Full Text PDF
Article Synopsis
  • * The research analyzed data from 465 kidney cancer patients and 256 living kidney donors, revealing high rates of post-surgery AKI, especially among donors, and varied progression of CKD depending on the type of surgery performed.
  • * Findings indicated that factors such as age and health conditions prior to surgery can predict CKD progression, emphasizing that both kidney cancer patients and living donors face considerable risks related to kidney function after surgery.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!